Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 10/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14718548 | 0.87 | DAO (0.47) | DAOGPR84DHODHPARP1 | |
| SCHEMBL16231718 | 0.86 | GPR84 (0.49) | DAOGPR84DHODHPARP1 | |
| SCHEMBL14718895 | 0.85 | DAO (0.51) | DAODHODHPARP1NR3C2HTR2B | |
| SCHEMBL30107675 | 0.85 | DAO (0.51) | DAODHODHPARP1NR3C2HTR2B | |
| SCHEMBL14719236 | 0.84 | DAO (0.57) | DAOGPR84 | |
| SCHEMBL18467392 | 0.84 | ESR1 (0.45) | DAOPARP1HTR2B | |
| SCHEMBL30107626 | 0.84 | DAO (0.56) | DAOGPR84COMT | |
| SCHEMBL14719044 | 0.84 | DAO (0.50) | DAOGPR84PARP1NR3C2 | |
| SCHEMBL14718871 | 0.84 | DAO (0.56) | DAOGPR84COMT | |
| SCHEMBL14719582 | 0.83 | GPR84 (0.52) | DAOGPR84DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-07 | — | — | US | claimed |
| US-20240036064-A1 | METHODS AND COMPOSITIONS FOR DETECTING COGNITIVE DISORDER | Sanford Burnham Prebys Medical Discovery Institute | 2024-02-01 | — | — | US | claimed |
| CN-115666526-A | Oral solid preparation | 武田药品工业株式会社 | 2023-01-31 | — | — | CN | claimed |
| EP-4114361-A1 | ORAL SOLID PREPARATIONS | Takeda Pharmaceutical Company Limited (JP) | 2023-01-11 | — | — | EP | claimed |
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-13 | — | — | US | claimed |
| US-11129828-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-28 | — | — | US | claimed |
| US-20200121678-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-04-23 | — | — | US | claimed |
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-05 | — | — | US | claimed |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-28 | — | — | US | claimed |
| EP-3113778-B1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-06 | — | — | EP | claimed |
| EP-3113778-A1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER | Takeda Pharmaceutical Company Limited (JP) | 2017-01-11 | — | — | EP | claimed |
| CN-106102743-A | For preventing or treating the pyridyl derivatives of incoordination illness | 武田药品工业株式会社 | 2016-11-09 | — | — | CN | claimed |
| US-9290456-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-22 | — | — | US | claimed |
| EP-2748149-B1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-10-21 | — | — | EP | claimed |
| WO-2015132608-A1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-11 | — | — | WO | claimed |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | claimed |
| US-20140336165-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-11-13 | — | — | US | claimed |
| EP-2748149-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2014-07-02 | — | — | EP | claimed |
| WO-2013027000-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | claimed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052281-A1 | NOVEL COMPOUNDS | ABCG2, F12, UGT1A1 | DAO 4565/4885GPR84 826/4885DHODH 2119/4885 |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885GPR84 2658/4885DHODH 9/4885 |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | DAO 2/4885GPR84 2658/4885DHODH 9/4885 |
| US-20200121678-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885GPR84 2658/4885DHODH 9/4885 |
| US-11129828-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | DAO 2/4885GPR84 2658/4885DHODH 9/4885 |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885GPR84 2658/4885DHODH 9/4885 |
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | DAO 2/4885GPR84 2658/4885DHODH 9/4885 |
| US-20140336165-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | DAO, DDO, DDC | DAO 1/4885GPR84 717/4885DHODH 5/4885 |
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885GPR84 2658/4885DHODH 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.